Literature DB >> 17700549

Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?

Marius E Kraenzlin1, Christian Meier.   

Abstract

Entities:  

Year:  2007        PMID： 17700549     DOI： 10.1038/ncpendmet0618

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  3 in total

Review 1.  Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.

Authors:  Piet Geusens
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

2.  Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women.

Authors:  Monika A Izano; Romain Neugebauer; Bruce Ettinger; Rita Hui; Malini Chandra; Annette L Adams; Fang Niu; Susan M Ott; Joan C Lo
Journal:  J Manag Care Spec Pharm       Date:  2019-06

3.  Determinants of Oral Bisphosphonate Use Beyond 5 Years.

Authors:  Monika A Izano; Joan C Lo; Bruce Ettinger; Susan M Ott; Bonnie H Li; Fang Niu; Rita L Hui; Romain Neugebauer; Annette L Adams
Journal:  J Manag Care Spec Pharm       Date:  2020-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.